DDInter393 DDInter1628
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Clarithromycin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) PRAF2
PRAF2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) regulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) CHERP
CHERP {u} (Gene) is regulated by {v} (Gene) MAP3K2
MAP3K2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is regulated by {v} (Gene) LTK
LTK {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) PRAF2
PRAF2 {u} (Gene) regulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Clarithromycin {u} (Compound) downregulates {v} (Gene) NPDC1
NPDC1 {u} (Gene) covaries with {v} (Gene) MKNK2
MKNK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) is upregulated by Ruxolitinib (Compound)
Clarithromycin (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates PRAF2 (Gene) and PRAF2 (Gene) is downregulated by Ruxolitinib (Compound)
Clarithromycin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) regulates SMNDC1 (Gene) and SMNDC1 (Gene) is upregulated by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates CHERP (Gene) and CHERP (Gene) is regulated by MAP3K2 (Gene) and MAP3K2 (Gene) is bound by Ruxolitinib (Compound)
Clarithromycin (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is regulated by LTK (Gene) and LTK (Gene) is bound by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates PRAF2 (Gene) and PRAF2 (Gene) regulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Clarithromycin (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) covaries with MKNK2 (Gene) and MKNK2 (Gene) is bound by Ruxolitinib (Compound)